We combined de novo designed isoform-specific minibinders with novel oligomeric scaffolds to modulate FGFR signaling. The FGF-mimetics were used to program cellular decision making and we found that the FGFRc-isoform is relevant in vascular differentiation for arterial cell fate.

Incidence of FGFR aberrations across cancer types

academic.oup.com/oncolo/advance…

👀 TAR-210 the Phase 1 study
Intravesical Erdafitinib in HR and IR NMIBC
In patient w/ FGFR alteration

🟢IR-NMIBC 87% CR in a CHEMOABLATION setting!!

🔵HR-NMIBC 82% CR

➡️intravesical treatment has a great futur!! No more TURBT soon 🥺?

🔵Does the higher prevalence of FGFR mutations in non-muscle invasive bladder cancer (NMIBC) while being less common in advanced stages indicate a lower likelihood of progression in patients with mutations?

🔵Is there a need to conduct mutation analysis again during disease…

1/ Pls✅out our work w/ a completely unexpected finding demonstrating that FGFR inhibition suppresses Treg proliferation in a cell autonomous manner in context of FGFR3 driven #bladdercancer
👇👇👇
buff.ly/3RYZ4Mu
jci.org/articles/view/…

Cover art credit: Riley S. Kim

#Target23
Clinical activity of #lirafugratinib (RLY-4008), a highly selective #FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the #ReFocus study.

1> Pan-FGFR tyrosine kinase inhibitors are less effective in patients with FGFR amplification, but…

The FGF/FGFR axis.🎯🎯
Co-driver alterations are often present, especially in cyclin genes.
Targeting both the FGFR axis and the co-driver axis is safe and active.
N-of-1 individualized therapy. 💡💡

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

Precision treatment making a difference for a CUP patient. FGFR alteration and positive PDL1 treated with pemigatinib snd immunotherapyb

Something NEW. TAR-210 releases erdafitinib slowly into the bladder by a novel release system. In BCG refractory FGFR selected High risk NMIBC 82-87% of patients were recurrent free at 1st cut off in the 2 cohort. This could have a major impact in NMIBC and MIBC #ESMO23

🔅ESMO-2023, hepatobiliary and pancreatic cancers
ESMO - Eur. Oncology EORTC

✅Biliary tract cancers

✔️Outcomes worse in extraheoatic CCA than intrahepatic with cis-gem
✔️tinengotinib as a FGFR2 inhibitor after progression with another FGFR inhibitor
✔️DESTINY-PanTumor02 trial,…

A frequent alteration in breast cancer. Difficult to tackle. We present data of FUTIBATINIB (FGFR inhibitor) in a cohort of TNBC with FGFR2 amplification. So much work to identify the responders: FGFR often not a driver oncogene. #SABCS23 #bcsm

My thoughts about THOR Cohort 2 at #ESMO23 :
📌 IO should be offered before than FGFR inhibitors in the sequence strategy to manage advanced urothelial tumors.
Higher responses may not compensate the lack of impact in OS and toxicity profile
📌 If EV-Pembro becomes standard in…

FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma based on THOR trial results. Janssen applied for EMA authorization on september 12. New game-changers on the horizon, this time in a selected FGFR population.

⚛️📖Biomarkers and targeted treatment in pancreatic cancer
ESMO - Eur. Oncology Oncology Advance

✅Review of an updated perspective
➡️BRCA1/2, MSI, TMB, KRAS, NTRK, NRG, FGFR, BRAF
➡️Drug delivery, cell therapies, vaccines

⁉️The POLO trial of olaparib did NOT show significant difference…

FGF/FGFR axis and cyclin alterations co-exist.🔥
Dual targeting needed.💡💡🎯🎯
Rewarding collaboration with colleagues across the country and in Brazil. 🇧🇷🇺🇸

What drug is this patient on...?

A patient with intrahepatic cholangiocarcinoma with FGFR2 fusion. Responding nicely to pemigatinib, an FDA-approved FGFR inhibitor. Tumor calcifications are sometimes seen and here is an example of that. Remember, sequence ALL biliary cancers!!!

鄭羽伸大学院生、中川誠人講師らの研究グループは、bFGFがFGFRとインテグリンに同時に結合することによる細胞内シグナルクロストークが、プライム型ヒトiPS細胞の未分化性維持に重要であることを明らかにしました。 #iPS細胞
cira.kyoto-u.ac.jp/j/pressrelease…

If you are in Torino attending the EACR, come to the poster P-0482 'N-Cadherin Expression and KRAS mutation status could predict response to Anti-FGFR Therapy'
#EACR2023

Novel mechanism of FGFR activation : galectins bind N-glycans of FGFR1 and trigger clustering of FGFR1, resulting in activation of the receptor and initiation of downstream signaling. They also activate an FGFR pool inaccessible for FGF1. tinyurl.com/47mfcax5

#glycotime